Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir

Multi-Center, Open-Label Study of the Effect of Indinavir, Efavirenz, and Adefovir Dipivoxil Combination Therapy in Patients Who Have Failed Nelfinavir

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00002220

Enrollment

120

Registered

2001-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Drug Resistance, Drug Therapy, Combination, Antiviral Agents, HIV Protease Inhibitors, Indinavir, RNA, Viral, Adenine, efavirenz

Brief summary

The purpose of this study is to compare the effectiveness of giving indinavir plus efavirenz plus adefovir dipivoxil to patients who have failed treatment with nelfinavir and patients who have never taken a protease inhibitor (PI). Effectiveness is measured by the number of patients who have a viral load (level of HIV in the blood) below 400 copies/ml after 48 weeks of treatment.

Detailed description

In this open-label, nonrandomized study, 120 HIV-infected patients are stratified into two groups: failed nelfinavir vs protease inhibitor-naive. All patients receive indinavir plus efavirenz plus adefovir dipivoxil plus and L-carnitine, orally. Plasma vRNA is measured every 4 weeks until Week 16, then every 8 weeks for the remainder of the 48-week study.

Interventions

DRUGEfavirenz

DRUGLevocarnitine

DRUGAdefovir dipivoxil

DRUGIndinavir sulfate

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients must have: * Serologically documented HIV infection. * Baseline CD4 count greater than or equal to 50 cells and vRNA greater than or equal to 10,000 copies/ml. * Parental consent for patients under 18. Nelfinavir-Failure Group: * Must have protease inhibitor experience solely with nelfinavir and be considered drug-adherent. * Must be candidate for changing therapy because of virologic failure and be receiving nelfinavir at entry (at least 16 weeks of nelfinavir plus NRTI therapy with at least a 10-fold decline in vRNA due to nelfinavir therapy and a subsequent increase toward the patient's baseline vRNA of at least 10-fold). Control Group: * Must have received any combination of currently licensed nucleoside reverse transcriptase inhibitors for at least 16 weeks. * Must be naive to efavirenz, adefovir dipivoxil, and other NRTI's.

Exclusion criteria

Prior Medication: Excluded: Control group: * Prior efavirenz, adefovir dipivoxil, or other non-nucleoside reverse transcriptase inhibitors. Required: Nelfinavir-failure patients: * At least 16 weeks of nelfinavir. Control group: * At least 16 weeks of any combination of currently licensed nucleoside reverse transcriptase inhibitors.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026